Synthesis of carbon-14-labelled peptides
- PMID: 31211429
- DOI: 10.1002/jlcr.3777
Synthesis of carbon-14-labelled peptides
Abstract
Carbon-14 (14 C)-labelled active pharmaceutical ingredients (APIs) and investigational medicinal products (IMPs) are required for phase 0/I to phase III mass balance and micro-dosing clinical trials. In some cases, this may involve the synthesis of 14 C-labelled peptides, and the analysis can be performed by accelerated mass spectrometry (AMS). The 14 C-peptide is typically prepared by the solid-phase peptide synthesis (SPPS) approach using custom-made glassware for the key coupling steps. Further modification of the purified 14 C-peptide can then be performed.
Keywords: accelerated mass spectrometry; biomolecules; carbon-14 peptides; solid-phase peptide synthesis.
© 2019 John Wiley & Sons, Ltd.
References
REFERENCES
-
- Marqus S, Pirogova E, Piva TJ. J Biomed Sci. 2017;24(21):201724-201721.
-
- Penner N, Xu L, Prakash C. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol. 2012;25(3):513-531.
-
- Pham P, Ramombordes C, Perret C, et al. Radiolabelling by tritium and [125I]iodine of an angiotensin II related peptide. J Label Compd Radiopharm. 1991;29(5):575-581.
-
- Reay P. Use of n-bromosuccinimide for the iodination of proteins for radioimmunoassay. Ann Clin Biochem. 1982;19(2):129-133.
-
- Enright HA, Malfatti MA, Zimmermann M, Ognibene T, Henderson P, Turteltaub KW. Use of accelerator mass spectrometry in human health and molecular toxicology. Chem Res Toxicol. 2016;29(12):1976-1986.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources